Healthcare / Drug Manufacturers - Specialty & GenericTokyo
$1198.00
-16.00 (-1.32%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-4.7B · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
53/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$68.8B
P/E
7.4x
↓EV/EBITDA
4.7x
↓ROE
6.7%
↑Gross Margin
45.8%
↓Debt/Equity
0.21
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+7.2%
FCF CAGR
—
FCF margin
-2.1%
FCF / Net income
-0.31x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $130.09B · net income $9.09B · FCF $-2.79B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $130.09B | $130.09B | $119.53B | $113.27B | $105.53B |
| Net Income | $9.09B | $9.09B | $5.47B | $4.72B | $3.93B |
| EBITDA | $17.55B | $17.55B | $11.60B | $10.81B | $9.00B |
| EPS | 158.17 | 158.17 | 92.74 | 82.44 | 68.62 |
| Gross Margin | 45.8% | 45.8% | 43.2% | 44.3% | 46.8% |
| Operating Margin | 9.7% | 9.7% | 5.2% | 4.5% | 4.7% |
| Net Margin | 7.0% | 7.0% | 4.6% | 4.2% | 3.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.21 | 0.21 | 0.16 | 0.17 | 0.17 |
| Current Ratio | 4.60 | 4.60 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.79B | $-2.79B | $-4.70B | $-7.40B | $3.66B |
| Returns | |||||
| ROE | 6.7% | 6.7% | 4.2% | 3.8% | 3.2% |
| Valuation | |||||
| P/E | 7.38 | 7.38 | 19.51 | 20.72 | 26.45 |
| EV/EBITDA | 4.69 | 4.69 | 9.56 | 9.23 | 10.96 |
| P/B | 0.50 | 0.50 | 0.79 | 0.78 | 0.84 |
| Growth & Yield | |||||
| Revenue Growth | 8.8% | 8.8% | 5.5% | 7.3% | — |
| EPS Growth | 70.6% | 70.6% | 12.5% | 20.1% | — |
| Dividend Yield | 2.1% | 2.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-12.4%
EPS terminal req.
$106.30
Spread vs growth
83.0%
5Y implied EPS CAGR
-4.1%
EPS terminal req.
$128.63
Spread vs growth
74.6%
10Y implied EPS CAGR
2.7%
EPS terminal req.
$207.15
Spread vs growth
67.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-16.4%
Start / end P/E
15.8x → 7.6x
EPS bridge
92.74 → 158.17
Residual
-36.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.